Minjuan Hu

510 total citations
28 papers, 322 citations indexed

About

Minjuan Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Minjuan Hu has authored 28 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Minjuan Hu's work include Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Lung Cancer Research Studies (10 papers). Minjuan Hu is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Lung Cancer Research Studies (10 papers). Minjuan Hu collaborates with scholars based in China. Minjuan Hu's co-authors include Baohui Han, Jun Lü, Yanwei Zhang, Fangfei Qian, Yanan Wang, Lele Zhang, Wei Zhang, Yuqing Lou, Shuyuan Wang and Jie Qian and has published in prestigious journals such as Journal of Controlled Release, International Journal of Cancer and Frontiers in Immunology.

In The Last Decade

Minjuan Hu

28 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Minjuan Hu China 11 208 186 86 82 37 28 322
Wenxiao Jia China 10 219 1.1× 157 0.8× 88 1.0× 95 1.2× 57 1.5× 25 374
Robyn R. Young United States 10 260 1.3× 152 0.8× 97 1.1× 75 0.9× 42 1.1× 24 344
Danilo Galizia Italy 10 179 0.9× 108 0.6× 68 0.8× 58 0.7× 35 0.9× 32 285
Adrian von Witzleben Germany 11 132 0.6× 129 0.7× 46 0.5× 91 1.1× 70 1.9× 33 315
Leonardo Rojas Colombia 10 147 0.7× 151 0.8× 61 0.7× 72 0.9× 18 0.5× 40 268
Se Kyu Kim South Korea 8 213 1.0× 194 1.0× 67 0.8× 128 1.6× 37 1.0× 11 391
Thiago Bueno de Oliveira Brazil 10 143 0.7× 100 0.5× 76 0.9× 56 0.7× 26 0.7× 35 299
Xin-Ke Zhang China 7 215 1.0× 118 0.6× 57 0.7× 65 0.8× 78 2.1× 9 359
Alberto Carretero-González Spain 9 195 0.9× 123 0.7× 75 0.9× 83 1.0× 60 1.6× 20 310
Zuyi Yang China 10 119 0.6× 167 0.9× 125 1.5× 184 2.2× 61 1.6× 20 350

Countries citing papers authored by Minjuan Hu

Since Specialization
Citations

This map shows the geographic impact of Minjuan Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minjuan Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minjuan Hu more than expected).

Fields of papers citing papers by Minjuan Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minjuan Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minjuan Hu. The network helps show where Minjuan Hu may publish in the future.

Co-authorship network of co-authors of Minjuan Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Minjuan Hu. A scholar is included among the top collaborators of Minjuan Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minjuan Hu. Minjuan Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, Minjuan, et al.. (2024). Cyclosporine successfully treats steroid-resistant checkpoint inhibitor-related pneumonitis: a case report. BMC Pulmonary Medicine. 24(1). 577–577. 1 indexed citations
2.
Li, Ru, Haiyi Deng, Qingyang Li, et al.. (2024). The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients. Frontiers in Oncology. 14. 1372532–1372532. 1 indexed citations
3.
Lü, Jun, Bo Han, Bo Han, et al.. (2023). PEG2000-PLA-based nanoscale polymeric micelles reduce paclitaxel-related toxicity in beagle dogs. Journal of Controlled Release. 362. 197–209. 4 indexed citations
4.
Chen, Yan, Changhao Zhong, Minjuan Hu, et al.. (2023). Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment. Frontiers in Immunology. 14. 1106090–1106090. 3 indexed citations
5.
6.
Wang, Yanan, Ya Chen, Fangfei Qian, et al.. (2022). Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma. Annals of Surgical Oncology. 29(9). 5666–5678. 5 indexed citations
7.
Liu, Zhichao, Yanan Wang, Yanwei Zhang, et al.. (2022). The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma. Cancer Medicine. 11(5). 1299–1309. 7 indexed citations
8.
Lü, Jun, Tianqing Chu, Hongyu Liu, et al.. (2022). Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update. Chinese Journal of Cancer Research. 34(1). 28–39. 7 indexed citations
9.
Chen, Ya, Yanan Wang, Minjuan Hu, et al.. (2021). Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC. Frontiers in Oncology. 11. 671228–671228. 18 indexed citations
10.
Wang, Yanan, Fangfei Qian, Ya Chen, et al.. (2021). Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung. Frontiers in Oncology. 11. 714549–714549. 5 indexed citations
11.
Chen, Ya, Yanan Wang, Shuyuan Wang, et al.. (2021). Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations. Frontiers in Oncology. 11. 681429–681429. 9 indexed citations
12.
Nie, Wei, Minjuan Hu, Qin Zhang, et al.. (2021). DUBR suppresses migration and invasion of human lung adenocarcinoma cells via ZBTB11-mediated inhibition of oxidative phosphorylation. Acta Pharmacologica Sinica. 43(1). 157–166. 18 indexed citations
13.
Zhang, Wei, Yanwei Zhang, Fangfei Qian, et al.. (2021). PlGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/β-catenin pathway. Cancer Cell International. 21(1). 18–18. 2 indexed citations
14.
Chen, Ya, Yanan Wang, Minjuan Hu, et al.. (2021). Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study. Frontiers in Oncology. 11. 691519–691519. 7 indexed citations
15.
Zhao, Yiming, Yu Dong, Ruiying Zhao, et al.. (2020). Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non–small-cell Lung Cancer in China. Clinical Lung Cancer. 21(5). e355–e362. 8 indexed citations
16.
Zhang, Lele, Jun Lü, Ruiqi Liu, et al.. (2020). Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells. Acta Pharmacologica Sinica. 41(10). 1357–1365. 25 indexed citations
17.
18.
Nie, Wei, Jie Qian, Midie Xu, et al.. (2020). A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab. OncoImmunology. 9(1). 1731072–1731072. 28 indexed citations
19.
Zhang, Yanwei, Beibei Sun, Minjuan Hu, et al.. (2020). CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients. Frontiers in Oncology. 10. 1049–1049. 12 indexed citations
20.
Lü, Jun, Wei Xu, Jie Qian, et al.. (2019). Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells. BMC Medical Genomics. 12(S2). 38–38. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wenxiao Jia Breakdown of academic impact, for papers by Robyn R. Young Breakdown of academic impact, for papers by Danilo Galizia Breakdown of academic impact, for papers by Adrian von Witzleben Breakdown of academic impact, for papers by Leonardo Rojas Breakdown of academic impact, for papers by Se Kyu Kim Breakdown of academic impact, for papers by Thiago Bueno de Oliveira Breakdown of academic impact, for papers by Xin-Ke Zhang Breakdown of academic impact, for papers by Alberto Carretero-González Breakdown of academic impact, for papers by Zuyi Yang
Rankless by CCL
2026